Medicine composition of tyrosine kinase inhibitor and histone deacetylase inhibitor
A technology of tyrosine kinase and deacetylase, which is applied in the field of drugs for the treatment of tumors, can solve the problems of poor drug resistance, insufficient tumor curative effect, and large clinical drug doses, and achieve the effect of delaying drug resistance and reducing drug resistance
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment Construction
[0023] According to the technical scheme of the present invention, this embodiment provides a drug combination of a tyrosine kinase inhibitor and a histone deacetylase inhibitor, the tyrosine kinase inhibitor is selected from imatinib, histone The sirtuin inhibitor is hemisodium valproate, and the combination of the two according to the mass ratio of 0.5:1~1:4 is only a further description of the present invention, not a specific combination of tyrosine kinase inhibitors and specific combinations. Concomitant use of protein deacetylase inhibitors is limited.
[0024] The dose of valproate adopts a low cytotoxic dose, and the clinically relevant dose is 100-1000 mg / d; the dose of imatinib adopts a clinical dose, and the clinically relevant dose is 50-800 mg / d. d, and used in combination with valproate.
[0025] The tyrosine kinase inhibitors include, but are not limited to, imatinib, dasatinib, nilotinib, gefitinib, etc.; the histone deacetylase inhibitors include, but are not...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com